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Abstract
Background: Chondromodulin-1 (ChM1), an endogenous anti-angiogenic factor expressed in cartilage, has been suggested to
inhibit invasion of endothelial cells into cartilage. In addition, the ectopic administration of ChM1 has been reported to suppress
tumorigenesis in vivo. However, it is unclear whether the anti-tumor effect is due to not only the anti-vascularization effect of
ChM1, but also its direct action against oncocytes. In the present study, we sought to determine whether ChM1 has a direct
action on tumor cells.
Methods: BrdU incorporation assay was performed on human umbilical vein endothelial cells (HUVECs), normal human dermal
fibroblasts (NHDFs), HepG2 cells and HeLa cells in the presence or absence of recombinant human ChM1 (rhChM1). An
adenovirus that expresses ChM1, Ad-ChM1, was established and applied to the tumor xenografted in vivo, and to in vitro tumor
cells cultured on plates or in soft agar. Cell cycle-related proteins and the phosphorylation of Erk, Akt, and GSK3β, the
downstream molecules of the extracellular matrix-integrin signaling pathways, in HepG2 cells treated with or without Ad-ChM1
were detected by western blot analysis. Luciferase reporter assays of STAT, GAS, and ISRE, which participate in another
cytokine signaling pathway, ware performed in HepG2, HeLa, and HUVEC cells.
Results: ChM1 suppressed BrdU incorporation in HUVECs and in HepG2 cells dose-dependently, but did not suppress BrdU
incorporation in NHDFs and HeLa cells cultured on plates. In soft agar, however, ChM1 suppressed the growth of HeLa cells,
as well as HepG2 cells. Western blot analyses demonstrated that ChM1 decreased the levels of cyclin D1, cyclin D3, and cdk6
and increased those of p21cip1 without affecting the phosphorylation levels of Erk, Akt, and GSK3β in HepG2 cells. The luciferase
reporter assay demonstrated that ChM1 suppressed the transcriptional activities of STAT and GAS but not of ISRE.
Conclusion: ChM1 directly suppressed the proliferation of tumor cells in an anchorage-independent manner. However, ChM1
did not alter the phosphorylation of downstream molecules, at which the signaling pathways through growth factor and cytokine
receptors converge with the anchorage-dependent pathway. Our results show that ChM1 has a direct anti-tumor effect;
moreover, this effect occurs by inhibiting the STAT signaling pathway.
Published: 31 May 2009
BMC Cancer 2009, 9:166 doi:10.1186/1471-2407-9-166
Received: 17 December 2008
Accepted: 31 May 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/166
© 2009 Mera et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:166 http://www.biomedcentral.com/1471-2407/9/166
Page 2 of 12
(page number not for citation purposes)
Background
Malignant tumor cells produce various growth factors that
induce angiogenesis to supply nutrition for their own
growth. Thus molecules that inhibit angiogenesis are
good candidates for anti-tumor agents [1]. Indeed, some
studies in which angiogenesis was targeted have provided
encouraging results. Recently, however, it was reported
that monotherapy with the monoclonal antibody beva-
cizmab, which targets vascular endothelial growth factor
(VEGF), or an endogenous anti-angiogenic agent such as
endostatin produced only moderate suppression of tumor
growth compared to a combined therapy that included a
cytotoxic agent [2,3]. These observations suggest that a
molecule with both cytotoxic and anti-angiogenic activi-
ties may have a stronger anti-cancer effect. However, such
a molecule has not been identified.
Chondromodulin-1 (ChM1) is a 25 kDa glycoprotein that
is expressed mainly in cartilage. ChM1 shows anti-ang-
iogenic activity and has been suggested to inhibit
endothelial cells from invading cartilage [4-6]. Recently,
we reported that the ectopic administration of ChM1 dra-
matically suppresses tumorigenesis in vivo [7], which sug-
gests that ChM1 acts directly against tumor cells. ChM1
can have either a positive or negative effect on cell prolif-
eration: It promotes the proliferation of chondrocytes and
osteoblasts [4,6,8], but suppresses growth of endothelial
cells and T-cells [5,9].
ChM1 also promotes anchorage-independent growth of
chondrocytes [6]. Anchorage-independent growth is a
characteristic of non-adherent cells, including oncocytes
[10], chondrocytes [11-14], and hemocytes [15,16]. On
the other hand, transforming growth factor β (TGFβ) also
modulates cell growth both positively and negatively.
TGFβ promotes anchorage-independent growth of
chondrocytes [6,11,12], but suppresses or promotes
anchorage-independent growth of tumor cells depending
on the type and state of the cells [14,17-19]. Thus, ChM1
may also suppress tumor cell growth.
Anchorage-dependent signaling involves extracellular
matrix-integrin complexes and their downstream mole-
cules such as Erk, Akt, and GSK3β, which are shared with
the signaling pathway activated by cytokine receptor stim-
ulation [10,20-22]. Abnormality in this signaling path-
way, of tumor suppressor proteins, or a combination of
both, constitutively activates oncocytes, thereby inducing
anchorage-independent tumor growth. The cytokine sign-
aling pathway involving the Signal Transducers and Acti-
vators of Transcription (STAT) protein [3,23-27], a latent
transcriptional factor activated by the Janus Kinase (JAK)
family of tyrosine kinase, is also modified in various types
of tumor cell. Therefore, the STAT signaling pathway may
also be involved in the putative action of ChM1.
The aim of the present study was to determine whether
ChM1 has a direct action on tumor cells. Here, we report
that ChM1 directly suppresses tumor cell anchorage-inde-
pendent growth by inhibiting the anchorage-independent
STAT signaling pathway.
Methods
Reagents and antibodies
Anti-ChM1 polyclonal antibody, kindly provided by Dr.
Hiraki (Department of Molecular Interaction and Tissue
Engineering, Institute for Frontier Sciences, Kyoto Univer-
sity, Kyoto, Japan), was used for western blot analysis
[28]. Other primary antibodies were purchased from Cell
Signaling Technology Inc (Boston, Massachusetts,) to
detect cell-cycle related proteins, Erk (p44/p42), Akt,
GSK3β, and their phosphorylated forms. The constructs of
pSTAT RE-TK hRluc (STAT-luc), pISRE RE-TK hRluc (ISRE-
luc), and pGAS RE-TK hRluc (GAS-luc), provided by Dr.
Yokoyama K., and obtained from RIKEN BioResource
Center, Tsukuba, Japan, were used for the luciferase
reporter assays.
Cell culture
HEK 293, HepG2 (human hepatocellular carcinoma),
HeLa (human uterine cervical adenocarcinoma), and PC-
3 (human prostate adenocarcinoma) cells were obtained
from the American Type Culture Collection (Rockville,
MD). The human osteosarcoma cell line, NOS-1, which is
osteoid inducible in xenografted tumors in nude mice,
was established previously from a 16 year-old male Japa-
nese patient [29,30]. HepG2 and HeLa cells were cultured
in DMEM (Gibco/Invitrogen, Grand Island, NY), PC-3
cells in Ham's F12K (Sigma-Aldrich, Inc., St. Louis, MO),
and NOS-1 cells in RPMI (Gibco) supplemented with
10% fetal bovine serum (FBS) at 37°C under 5% CO2 in
air. Human umbilical vein endothelial cells (HUVECs)
and normal human dermal fibroblasts (NHDFs) were
obtained commercially (Cambrex, Walkersville, MD).
HUVECs were grown in EGM2 medium (EBM complete
medium with supplements; Sanko-Junyaku, Tokyo,
Japan), and NHDFs in FGM2 medium (FBM medium
with supplements; Sanko-Junyaku) at 37°C under 5%
CO2 in air. Cells were used at passages 2 through 4 after
acquisition.
DNA synthesis assay (BrdU incorporation)
HUVECs and NHDFs were harvested with trypsin/EDTA
and suspended in EGM2 and FGM2 as appropriate. The
cells were seeded at 3 × 104 cells/ml into a 96-well multi
titer plate (100 μl/well) and cultured for 24 hours. The
cells were then starved in 0.5% FBS containing Opti-MEM
for 12 hours and stimulated with 10 ng/ml FGF-2 (Pepro-
Tech EC, London, UK) in either the presence or absence of
25  μg/ml rhChM1 for another 24 hours. Cells were
labeled with BrdU during the last 3 hours of this incuba-BMC Cancer 2009, 9:166 http://www.biomedcentral.com/1471-2407/9/166
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tion. HepG2 cells were harvested with trypsin/EDTA and
suspended at a density of 5 × 103 cells/ml in 10% FBS con-
taining DMEM. HeLa cells were harvested similarly and
suspended at a density of 6 × 104 cells/ml. Cells were then
seeded into a 96-well multi titer plate (100 μl per well),
and cultured for an additional 36 hours. The medium was
replaced with one containing either 10 μg/ml or 25 μg/ml
rhChM1, BrdU was added, and the cells were cultured for
6, 12 or 24 hours. BrdU incorporation by the cells was
measured at least in triplicate at each time point using a
cell proliferation ELISA BrdU colorimetric kit according to
the manufacturer's instructions (Roche, Basel, Switzer-
land). Absorbances at 450 nm, referenced at 655 nm, were
measured using a Model 680 Microplate Reader (Bio-Rad,
Hercules, CA)
Adenovirus preparation
The human ChM1 cDNA expression vector (pcDNA3-
ChM1) was provided by Dr. Hiraki (Department of
Molecular Interaction and Tissue Engineering, Institute
for Frontier Sciences, Kyoto University, Kyoto, Japan).
This cDNA was inserted into a cassette cosmid carrying an
adenovirus type-5 genome lacking the E1A, E1B and E3
regions, and in which the Swa I cloning site is flanked by
the CAG promoter at the 5' end and by a rabbit globin
poly (A) sequence at the 3' end (Takara Bio Inc., Shiga,
Japan). In 293 cells, recombination between the homolo-
gous regions of the linearized transfer cosmid vector and
the adenovirus genome resulted in formation of the com-
plete adenoviral recombinant that contains the ChM1
cDNA. Before use in experiments, the adenovirus was
purified by sequential centrifugation in double CsCl step
gradients as previously described [31]. Titers of viral
stocks were determined by a plaque assay of 293 cells.
Viral suspensions were stored at -80°C. The virus was
thawed on ice prior to use.
Adenovirus treatment in vivo
Six- to eight-week old BALB/c athymic nude mice (Clea
Japan Inc., Tokyo, Japan) were used. Animal experiments
were performed in accordance with the institutional
guidelines of the university committee on the use and care
of animals. Mice were inoculated with 5 × 106 HepG2 cells
in the flank and tumors were allowed to grow to a volume
of 150 mm3. Animals were divided into three treatment
groups: Ad-ChM1 injection (n = 6); Ad-LacZ injection (n
= 6); and injection of control vehicle (Phosphate-Buffered
Saline, PBS) (n = 6). Adenovirus vectors (1 × 108 plaque
forming units/100 μl) were injected directly into the foci
center on days 0, 2 and 4 of treatment. Tumor length and
width were measured with calipers over a period of five
weeks. Tumor volume was calculated as (length ×
width2)/2.
Counting the number of total cells and viable cells in vitro
Approximately 0.5~2.5 × 104 cells were plated onto 35
mm culture plates and cultured for 24 hrs. Cells were then
infected with Ad-ChM1 or Ad-LacZ as a control, at an
appropriate multiplicity of infection (MOI) and were fur-
ther cultured. The MOI for each cell line was selected to
produce the optimum effect of ChM1 without cytotoxicity
by Ad-LacZ. The total number of cells was counted using
a hemocytometer at 24 hrs, 36 hrs, 48 hrs, and 72 hrs after
infection with adenoviruses. Viable cells were identified
using the trypan blue exclusion method and were counted
at each sampling interval. These experiments were carried
out at least in triplicate.
Anchorage-independent growth assay
HepG2 and HeLa cells were cultured on 35 mm culture
plates and infected with adenoviruses as described above.
Six hours (6 hrs) after adenovirus infection, colony forma-
tion assays were performed. The cells were detached and
suspended in a culture medium containing 0.68% malt-
ing agar (Sigma-Aldrich). The cell suspension was then
plated on culture medium containing 0.4% agarose that
had been allowed to harden beforehand. The cells were
cultured in a volume of 300 μl for 21 days with changes to
fresh medium every 3 to 4 days. The numbers and sizes of
the colonies were measured under a phase contrast micro-
scope on days 7, 14, and 21 of culture. The experiment
was carried out in triplicate.
Western blotting
To detect ChM1 and cell-cycle related proteins, the culture
medium was collected and subjected to trichloroacetic
acid (TCA) precipitation. The pellet produced by TCA pre-
cipitation was resolved in RIPA buffer containing a pro-
tease inhibitor cocktail (Sigma-Aldrich) and PMSF
(500:1:1). For whole cell extracts, cells were scraped, lysed
with RIPA buffer, and the lysate diluted with an equal vol-
ume of buffer containing 2-mercaptoethanol.
Xenografted tumor specimens were harvested 48 hrs after
adenoviral infection, followed by homogenization in lysis
buffer (8 M Urea, 0.2% sodium dodecyl sulfate, 0.8% Tri-
ton X-100, 3% 2-mercaptoethanol). Insoluble materials
were removed by centrifugation. The supernatants were
boiled for 3 min and stored at -20°C. For SDS-PAGE, pro-
teins (10~80 μg/lane) were run on 8~15% polyacryla-
mide slab gels and transferred to polyvinylidene
difluoride membranes. The membranes were blocked
with 5% skimmed milk in TBS with 0.1% Tween 20 (TBS-
T) for 1 hr at room temperature, and incubated overnight
at 4°C with primary antibodies diluted at 1:1000 to
1:4000. After washing at least twice in TBS-T, the mem-
branes were incubated with a horseradish peroxidase-con-
jugated secondary antibody (diluted 1:25000 with TBS-T)BMC Cancer 2009, 9:166 http://www.biomedcentral.com/1471-2407/9/166
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at room temperature for 1 hour. The membrane was
washed twice with TBS-T and immunoreactivity was visu-
alized using the Immobilone western blotting detection
system (Millipore, Billerica, MA).
Films of cell-cycle related proteins were developed and
scanned, and bands were analyzed as a ratio of target pro-
tein/α-tubulin control using the Scion Image for Win-
dows program, version 4.02.
Luciferase reporter assay
Three reporter constructs were obtained from RIKEN BRC
(Tsukuba, Japan). The nucleotide sequences of the
response elements were as follows: 5'-gatccagttcccgt-
caatcg-3' for STAT, 5'-gatccagaaacaaaaacaag-3' for ISRE,
and 5'-gatccttccgggaattctgggaag-3' for GAS. These con-
structs express Renilla luciferase. We prepared a reference
construct by digesting the HSV-TK promoter, between the
BamH1 site and Hind III sites, from the pRL-TK vector
(Promega Corporation, Madison, WI, USA) that expresses
Renilla luciferase, and cloning this fragment into the
pGL4.18 [luc2p/Neo] vector (Promega) that expresses Fire-
fly luciferase.
Cells were infected with virus and cultured for 12 hours.
They were then washed twice with culture medium and
then transfected with various luciferase expression vectors
by the lipofection method using Fugene-6 (Roche Diag-
nostics). Twenty-four hours after transfection, the cells
were harvested and a Dual-Luciferase TM reporter assay
system (Promega) was used for sequential measurement
of Firefly and Renilla luciferase activities using the specific
substrates beetle luciferin and coelenterazine, respec-
tively. Quantification of luciferase activities and calcula-
tion of relative ratios were carried out using a
luminometer (TD-20/20, Turner Designs, Sunnyvale,
CA). In these experiments, at least three independent
transfections were performed.
Statistical analysis
Student's t-test was performed for group comparisons of
BrdU incorporation on HUVECs and NHDFs. Fisher's
protected least significant difference procedure was per-
formed after repeated-measures analysis of variance
(ANOVA) for group comparisons of BrdU incorporation
on HepG2 and HeLa cells, and for the comparison of luci-
ferase reporter assays on HepG2, HeLa, and HUVECs.
Results
Recombinant human ChM1 suppresses DNA synthesis in 
some tumor cells
The effect of the rhChM1 protein on DNA synthesis was
examined using a BrdU incorporation assay. At a concen-
tration of 25 μg/ml, rhChM1 suppressed BrdU uptake in
HUVECs with or without FGF-2 (Figure 1A), but not in
NHDFs (Figure 1B). The presence of FGF-2 in the culture
medium increased the uptake of BrdU and amplified the
effect of ChM1 in HUVECs (Figure 1A). These results are
consistent with those reported previously [5,8,32].
Recombinant human ChM1 also suppressed BrdU uptake
by HepG2 cells. This effect first became evident at 12
hours after the addition of ChM1 and further increased at
24 hours in a dose-dependent manner (Figure 1C). In
contrast, rhChM1 did not affect BrdU uptake by HeLa cells
(Figure 1D). As our supply of rhChM1 was limited, we
used adenovirus carrying ChM1 cDNA (Ad-ChM1) in sub-
sequent experiments.
Expression of human ChM1 protein induced by adenovirus 
vector
Cells were transfected with Ad-ChM1 and cultured. Cell
lysates and culture medium supernatants were analyzed
for ChM1 protein by western blotting. It has been
reported that ChM1 is first produced as a 38 kDa precur-
sor that is then digested by furin to form a 25 kDa mono-
mer [32,33]. Two monomers form a dimer that is secreted
and is then localized on the plasma membrane as a mon-
omer with a modification of the sugar chains (approxi-
mately 25 kDa). In our study, we obtained data consistent
with those expected of ChM1; an example of a western
blot is shown in Figure 2A.
Ad-ChM1 inhibits tumor growth in vivo
BALB/c athymic mice were inoculated with HepG2 cells
and the consequent tumors were allowed to grow to a vol-
ume of 150 mm3. In mice injected with vehicle only or
Ad-LacZ, the tumors continued to grow and showed a 15-
fold increase (150 mm3 vs 2395.5 mm3) in size by day 24
(Figure 2B). In contrast, Ad-ChM1 injection not only pro-
duced complete inhibition of tumor growth, but also
diminished tumor size significantly (150 mm3 vs 12 mm3;
Figure 2B). Tumors actually disappeared completely in 4
of the 6 mice injected with Ad-ChM1. These data are in
good agreement with our previous observations.
Ad-ChM1 affects the growth of some tumor cell lines in 
vitro
We next examined the effect of Ad-ChM1 on various
tumor cell lines in vitro. Transfection with Ad-ChM1 sig-
nificantly reduced cell growth in HepG2, PC-3 and NOS-
1 cell cultures at 36 hours and thereafter (Figure 2C) com-
pared to the vehicle- or Ad-LacZ treated groups, but did
not affect the growth of HeLa cells. Trypan blue staining
revealed that in all cell lines, most of the cells on each cul-
ture plate were viable at 48 and 72 hours, although there
was a slight decrease in the proportion of viable cells at 72
hours (data not shown). Infection efficiency was adjusted
by setting the MOI to ensure that more than 80% of the
Ad-LacZ-treated cells were stained in an X-gal assay (data
not shown).BMC Cancer 2009, 9:166 http://www.biomedcentral.com/1471-2407/9/166
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ChM1 alters expression of cell cycle-related proteins in 
HepG2 cultured on plates
To investigate the mechanism of ChM1-induced suppres-
sion of tumor cell growth, we examined the expression
levels of cell cycle-related proteins in HepG2 cells in vitro
by western blotting analysis. As depicted in Figure 2D(a),
Ad-ChM1 altered the levels of some of cell cycle-related
proteins by 36 hours after infection and the effect was
maintained up to 48 hours. In a corresponding plot of the
densitometry analysis shown in Figure 2D(b), the levels of
cyclin D1, cyclin D3, and cdk6 were significantly
decreased by Ad-ChM1. In contrast, Ad-ChM1 caused up-
A BrdU incorporation assay indicated that rhChM1 directly suppressed DNA synthesis of HUVECs (A) and HepG2 cells (C)  cultured on plates Figure 1
A BrdU incorporation assay indicated that rhChM1 directly suppressed DNA synthesis of HUVECs (A) and 
HepG2 cells (C) cultured on plates. rhChM1 significantly inhibited DNA synthesis in HUVECs, with or without FGF-2 (A), 
but did not in NHDFs with FGF-2 (B). HepG2 and HeLa cells were cultured in growth medium for 36 hrs, and then in fresh 
growth medium containing rhChM1 for the next period as indicated. rhChM1 inhibited DNA synthesis of HepG2 in a dose-
dependent manner (C), but had no effect on HeLa cells (D). Each column and bar represent the mean and SD (n = 4). *: p < 
0.05; **: p < 0.001; NS: not significant.BMC Cancer 2009, 9:166 http://www.biomedcentral.com/1471-2407/9/166
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The effect of ChM1 on growth of tumor cells cultured on plates Figure 2
The effect of ChM1 on growth of tumor cells cultured on plates. A. Western blot analysis of the expression of trans-
fected ChM1 in cells and xenografted tumors. ChM1 protein was detected in cells 8 hrs after transfection and increased in a 
time-dependent manner (left panel). The amount of protein secreted into the medium also increased in a time-dependent man-
ner (middle panel). The protein was detected in xenografted tumor specimens harvested 48 hrs after transfection (right panel). 
The diffuse 25 kDa band corresponds to the monomer and glycosylated forms of ChM1 and the bands at approximately 38 
kDa and 50 kDa correspond to the precursor and dimerized forms of ChM1, respectively. B. The effect of ChM1 on the 
growth of implanted HepG2 cells in athymic mice. Adenoviral gene therapy was initiated when tumors attained a volume of 
150 mm3. ChM1 caused a complete suppression of tumor growth. Each point and bar represents the mean and SD (n = 6). C. 
ChM1 growth suppression of tumor cells cultured on plates. The inhibitory effect of ChM1 was observed 36 hrs after transfec-
tion in HepG2, PC-3 and NOS-1, but not in HeLa cells (n = 4). Each point and bar represents the mean and SD (n = 4). D. 
ChM1 alters the levels of cell cycle-related proteins in HepG2 cells cultured on plates. (a) Western blot analysis demonstrated 
that ChM1 altered the levels of some of cell cycle-related proteins. (b) Corresponding densitometry analysis showed that 
ChM1 significantly decreased from 24 hours, while cdk6 protein decreased from 36 hours, after adenoviral infection. The level 
of cyclin D3 protein was significantly decreased by ChM1 at 24 hours and 36 hours. In contrast, ChM1 significantly increased 
the level of p21cip1, a cdk inhibitor, at 12 hours and 36 hours.BMC Cancer 2009, 9:166 http://www.biomedcentral.com/1471-2407/9/166
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regulation of p21cip1, a cdk inhibitor, at 12 hours and 36
hours. Results of repeated experiments were similar, but
the signal contrasts of those proteins were different due to
exposure conditions of each membrane. RT-PCR analysis
demonstrated that the levels of gene expression of these
cell cycle-related proteins were unaffected by viral infec-
tion (data not shown).
ChM1 suppresses anchorage-independent growth of 
HepG2 and HeLa cells
We next examined the effect of ChM1 on anchorage-inde-
pendent growth, which is a hallmark of tumor cells. At 6
hours after infection with Ad-ChM1, HepG2 and HeLa
cells were detached from the plates, suspended in soft aga-
rose gel and a colony formation assay was carried out.
Colonies were first detected at 4 days in control cultures
(Figure 3A) and continued to increase in size with time
(Figure 3B). Ad-ChM1 infection markedly suppressed the
total number of colonies and of large colonies in the
HepG2 cell cultures. These data are consistent with those
shown in Figure 1C and 2C that were obtained from cells
grown on plates. Ad-ChM1 markedly suppressed the
number of colonies in HeLa cell cultures. This result is in
sharp contrast to the data obtained from culturing HeLa
cells on plates (Figures 1D and 2C). Ad-LacZ infection
slightly reduced the number of colonies, and this reduc-
tion was significant for HepG2 cells at 21 days (Figure
3B). These data clearly demonstrate that ChM1 is capable
of suppressing anchorage-independent growth of HepG2
and HeLa cells, a result that is consistent with its in vivo
anti-tumor effect (Figure 2B and ref [7]). ChM1 was more
effective in HepG2 than HeLa cells, and the reduction in
total colony number was 80% vs 50% at day 14 and
87.5% vs 70% at day 21, respectively.
Effect of ChM1 on downstream molecules of the 
extracellular matrix-integrin signaling pathway
As described above, we demonstrated that ChM1 directly
suppressed anchorage-independent tumor cell growth.
The mechanism of this action, however, was difficult to
elucidate, since neither the receptors nor the downstream
signaling molecules have been identified. Anchorage-
dependent signaling utilizes integrins and their down-
stream signaling pathway, which converges with one of
the anchorage-independent pathways that includes sign-
aling molecules such as Akt, Erk, and GSK3β [10,20-22].
We examined this pathway first using western blot analy-
sis and found that phosphorylation of Akt, Erk and GSK3β
was unaffected (Figure 4).
ChM1 modulates the STAT pathway
The luciferase reporter assay demonstrated that Ad-ChM1
suppressed the promoter activity of STAT-luc and GAS-luc,
but did not affect ISRE-luc promoter activity in HepG2,
HeLa and HUVECs cultured on plates (Figure 5). The
three cell types showed similar patterns of response to Ad-
ChM1. As described above, the growth of HeLa cells cul-
tured on plates was not affected by ChM1 (Figure 2C).
Nevertheless, the STAT pathway was suppressed by ChM1
in HeLa cells in a similar manner to HepG2 cells and
HUVECs (Figure 5), indicating that ChM1 caused growth
inhibition.
Discussion
Previously, we reported that rhChM1 inhibits growth of
chondrosarcomas in vivo [7], but our understanding at
that time was that the mechanism of the inhibitory effect
was solely due to the anti-angiogenic activity of ChM1. In
this study, we demonstrated that ChM1 has in vivo and in
vitro  anti-tumor activity against the hepatocyte tumor
cells, HepG2, and that the effect is due not only to its anti-
angiogenic activity but also to direct inhibition of tumor
cell growth. Moreover, our results showed that the Jak/
STAT signaling pathway is one of the targets of ChM1
action.
Monotherapy with the anti-VEGF antibody, bevacizmab,
or an endogenous anti-angiogenic agent such as endosta-
tin caused only a moderate suppression of tumor growth
compared with a combined therapy with a cytotoxic agent
[2,3]. These results indicate that a molecule with both
anti-angiogenic and direct cytotoxic activity should be
superior for the treatment of patients with malignant
tumors. In this regard, our finding that ChM1 has the abil-
ity not only to inhibit angiogenesis, but also to inhibit
tumor growth is of interest. ChM1 is the first example of
an endogenous molecule with both anti-angiogenic and
cytotoxic activities and our results suggest that this mole-
cule warrants further in vivo study in the future.
In addition to its anti-angiogenic activity, ChM1 is also
known to have chondrocyte modulating activity [4,6],
bone remodeling activity [34], and T-cell suppressing
activity [9]. In particular, ChM1 also promotes the
anchorage-independent growth of chondrocytes [6].
Anchorage-independent growth is a characteristic of non-
adherent cells, including oncocytes [10], chondrocytes
[11-14], and hemocytes [15,16]. As is shown in Figure 2,
the growth of HeLa cells cultured on plates was not
affected by ChM1, whereas the growth of HepG2, PC-3
and NOS-1 cells was significantly suppressed. In contrast,
the growth of HeLa cells cultured in soft agarose gel was
suppressed by ChM1 in a similar fashion to HepG2 cells,
although the effect on HeLa cells was slightly less (Figure
3B). These data indicate that ChM1 inhibits the anchor-
age-independent growth of tumor cells.
Moreover, our observations also provide some suggestion
as to why the results of plate culture produces conflicted
with those obtained from soft agarose gel culture. TheBMC Cancer 2009, 9:166 http://www.biomedcentral.com/1471-2407/9/166
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The effect of ChM1 on colony formation by tumor cells Figure 3
The effect of ChM1 on colony formation by tumor cells. A. HepG2 cells with or without adenoviral infection cultured 
in agarose gel for 21 days. On day 21, HepG2 cells infected with Ad-ChM1 formed fewer colonies, compared to cells infected 
with Ad-LacZ and to non-treated cells. Image magnification ×8. B. Effect of ChM1 on colony formation by HepG2 and HeLa 
cells. ChM1 not only reduced the number of colonies but also the size of colonies formed by HepG2 and HeLa cells. The effect 
of ChM1 on HeLa cells observed here is in stark contrast to its ineffectiveness on cells cultured on plates (Figure 2C). This 
results suggest that ChM1 suppresses anchorage-independent growth. Each point and bar represents the mean and SD (n = 3).BMC Cancer 2009, 9:166 http://www.biomedcentral.com/1471-2407/9/166
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luciferase reporter assay, carried out on cells cultured on
plates, demonstrated that ChM1 suppressed the promoter
activity of STAT-luc and GAS-luc in HeLa cells to a similar
extent as in HepG2 cells and HUVECs. This appears to be
inconsistent with the fact that ChM1 inhibited the growth
of HepG2, but not HeLa cells cultured on plates. When
the basal promoter activities of STAT-luc and GAS-luc
were examined, however, HepG2 cells were found to have
the highest levels, followed by HUVECs. In contrast, the
basal levels of HeLa cells were much lower than that of the
other cells(data not shown). Thus, the basal promoter
activities of STAT-luc and GAS-luc may be negligible in
HeLa cells. Taken together with the observation that the
growth of HeLa cells on plates was not affected by ChM1,
these data suggest that ChM1 inhibits the anchorage-inde-
pendent growth of cells, and, therefore, its effect on cells
cultured in soft agarose gel may be achieved by inhibition
of the Jak/STAT pathway. When cells are cultured on
plates, however, the effect of ChM1 on cell growth varies
depending upon the degree to which the cells rely on the
Jak/STAT pathway for growth. Thus, the growth of HeLa
cells cultured on plates was unaffected by ChM1, since
anchorage-dependent growth plus the anchorage-inde-
pendent non-Jak/STAT pathway may contribute to
growth. This explanation is consistent with our observa-
tion that phosphorylation of Akt, Erk and GSK3β, signal-
ing molecules downstream of integrin-mediated signal
transduction [10,20-22] and the anchorage-independent
non-Jak/STAT pathway, was not affected by ChM1.
However, it is unclear how ChM1 activates intracellular
signaling pathways and whether there are specific recep-
tors for ChM1. We have shown that ChM1 suppresses the
promoter activity of STAT-luc and GAS-luc, but not of
ISRE-luc. ChM1 may act through one or more of the fol-
lowing mechanisms: 1) by recruiting protein tyrosine
phosphatase family members such as SHP which inacti-
vate Jak; 2) by recruiting SOCS and/or PIAS to degrade
STAT dimers; or 3) by directly or indirectly inhibiting
cofactors that form complexes with STAT dimers [24,35].
Obviously, further study is required to examine these
mechanisms.
The cytotoxic action of ChM1 may be due to growth
arrest, apoptosis or a combination of both. Our results
strongly indicate that ChM1 mainly causes growth arrest.
First, ChM1 inhibited DNA synthesis (Figure 1) and sup-
pressed cell proliferation during culture on plates (Figure
2C), as well as in soft agar (Figure 3). Second, ChM1
down-regulated proteins such as cyclinD1, cyclinD3, and
cdk6 that promote cell division, and up-regulated cdk
inhibitors such as p21cip1 (Figure 2D). Third, cells treated
with ChM1 were mostly viable and the number of apop-
totic cells was negligible throughout the culture period
(data not shown). Taken together, these data suggest that
the cytotoxic effect of ChM1 is mainly due to cell cycle
arrest, and that apoptosis does not play an important role,
if any. To some extent, our data contradict a recent obser-
vation that ChM1 induces apoptosis of vascular endothe-
lial cells [36]. The reasons for this inconsistency are not
clear at present, but may be due to the use of different cell
types and/or experimental conditions in the two studies.
Possibly, the effect of ChM1 varies between cell types
depending on differences in cell cycle regulation and the
balance of signaling pathways that can be directly or indi-
rectly affected by the protein (see discussion above). Our
study suggests that ChM1 suppresses the growth of tumor
cells by directly arresting the cell cycle and that apoptosis
does not play a major role.
Conclusion
We have demonstrated that ChM1 produces an anti-
tumor effect not only by inhibiting angiogenesis but also
by inducing growth arrest of tumor cells, and by directly
suppressing the proliferation of tumor cells in an anchor-
age-independent manner. However, ChM1 did not alter
the phosphorylation of the downstream molecules at
which the signaling pathways through receptors for
growth factors and cytokines converge with the anchor-
age-dependent pathway. The mechanism of the induced
growth arrest appears to involve the anchorage-independ-
ent Jak/STAT pathway.
The effect of ChM1 on the downstream pathway of extracel- lular matrix-integrin signaling Figure 4
The effect of ChM1 on the downstream pathway of 
extracellular matrix-integrin signaling. Western blots 
showing phosphorylation levels of Erk, Akt, and GSK3β, the 
downstream molecules of the extracellular matrix-integrin 
signaling pathway. ChM1 had no effect on phosphorylation 
levels of these proteins at 8 and 24 hours after adenovirus 
infection.BMC Cancer 2009, 9:166 http://www.biomedcentral.com/1471-2407/9/166
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ChM1 is the first example of an endogenous molecule that
possesses two different anti-tumor actions. Our results
clearly indicate that this molecule warrants further study
in vivo.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
HM and HK conceived the project and contributed to its
design, HM mainly performed the experiments and
wrote/reviewed/edited the manuscript, HK performed
adenovirus preparation and animal experiments, and co-
wrote part of the manuscript. TY and OI supervised the
project and contributed to its design, analysis and inter-
pretation of the data. MMA supported cell culture and
western blotting analysis, interpreted the data, for which
they are due special thanks. TH, HK, HY supervised and
supported the project particularly aspects involving
ChM1. NK contributed to amplification of the adenovirus
and suggested the experiment. AO contributed to the
finance of the project. NE contributed to the finance of the
project, conceived and supervised the project. HK contrib-
uted to organization of the project, analyzed and inter-
ChM1 modulates the STAT pathway Figure 5
ChM1 modulates the STAT pathway. The effect of ChM1 on signal transduction pathways analyzed using a luciferase 
assay. ChM1 inhibited transcriptional activation through the STAT-luc by 30% in HepG2 and HeLa cells and by 40% in 
HUVECs. ChM1 inhibited transcriptional activation through the GAS-luc by 40% in HepG2 and HeLa cells and by 60% in 
HUVECs. In contrast, ChM1 did not affect transcriptional activity through the ISRE-luc in these cell lines. Each column and bar 
represent a mean and SD (n = 4). (*: p < 0.05; **: p < 0.001).BMC Cancer 2009, 9:166 http://www.biomedcentral.com/1471-2407/9/166
Page 11 of 12
(page number not for citation purposes)
preted the data and co-wrote the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
Dr. Hiraki Y., Department of Molecular Interaction and Tissue Engineering, 
for providing the polyclonal antibody and for valuable suggestion for an 
experimental technique.
pSTAT RE-TK hRluc, pISRE RE-TK hRluc, and pGAS RE-TK hRluc depos-
ited by Dr. Yokoyama K. were provided by the DNA Bank, RIKEN BioRe-
source Center, Tsukuba, Japan, with the support of the National Bio-
Resources Project of Ministry of Education, culture, Sports, Science and 
Technology, Japan(MEXT).
Dr. Matsuda J. PhD, Venture Business Laboratory, Niigata University, Nii-
gata, Japan, provided valuable opinions and techniques about producing and 
the arrangement of the figure.
This study was supported by a Grant for Promotion of Niigata University 
Research Project (to HK), by a grant from the Japan Orthopaedics and 
Traumatology Foundation, Inc. (to NE and AO) and by a Grant-in Aid from 
the Ministry of Education, Culture, Sports, Science and Technology (MEXT) 
(No.16390531) (to HK).
References
1. Folkman J: Anti-angiogenesis: new concept for therapy of solid
tumors.  Ann Surg 1972, 175(3):409-416.
2. Jain S, Watson MA, DeBenedetti MK, Hiraki Y, Moley JF, Milbrandt J:
Expression profiles provide insights into early malignant
potential and skeletal abnormalities in multiple endocrine
neoplasia type 2B syndrome tumors.  Cancer Res 2004,
64(11):3907-3913.
3. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX,
Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, et al.: Phase II
study of recombinant human endostatin in patients with
advanced neuroendocrine tumors.  J Clin Oncol 2006,
24(22):3555-3561.
4. Hiraki Y, Tanaka H, Inoue H, Kondo J, Kamizono A, Suzuki F: Molec-
ular cloning of a new class of cartilage-specific matrix, chon-
dromodulin-I, which stimulates growth of cultured
chondrocytes.  Biochem Biophys Res Commun 1991, 175(3):971-977.
5. Hiraki Y, Inoue H, Iyama K, Kamizono A, Ochiai M, Shukunami C,
Iijima S, Suzuki F, Kondo J: Identification of chondromodulin I as
a novel endothelial cell growth inhibitor. Purification and its
localization in the avascular zone of epiphyseal cartilage.  J
Biol Chem 1997, 272(51):32419-32426.
6. Inoue H, Kondo J, Koike T, Shukunami C, Hiraki Y: Identification of
an autocrine chondrocyte colony-stimulating factor: chon-
dromodulin-I stimulates the colony formation of growth
plate chondrocytes in agarose culture.  Biochem Biophys Res
Commun 1997, 241(2):395-400.
7. Hayami T, Shukunami C, Mitsui K, Endo N, Tokunaga K, Kondo J,
Takahashi HE, Hiraki Y: Specific loss of chondromodulin-I gene
expression in chondrosarcoma and the suppression of tumor
angiogenesis and growth by its recombinant protein in vivo.
FEBS Lett 1999, 458(3):436-440.
8. Mori Y, Hiraki Y, Shukunami C, Kakudo S, Shiokawa M, Kagoshima M,
Mano H, Hakeda Y, Kurokawa T, Suzuki F, et al.: Stimulation of
osteoblast proliferation by the cartilage-derived growth pro-
moting factors chondromodulin-I and -II.  FEBS Lett 1997,
406(3):310-314.
9. Setoguchi K, Misaki Y, Kawahata K, Shimada K, Juji T, Tanaka S, Oda
H, Shukunami C, Nishizaki Y, Hiraki Y, et al.: Suppression of T cell
responses by chondromodulin I, a cartilage-derived angio-
genesis inhibitory factor: therapeutic potential in rheuma-
toid arthritis.  Arthritis Rheum 2004, 50(3):828-839.
10. Schwartz MA: Integrins, oncogenes, and anchorage independ-
ence.  J Cell Biol 1997, 139(3):575-578.
11. Kato Y, Iwamoto M, Koike T: Fibroblast growth factor stimu-
lates colony formation of differentiated chondrocytes in soft
agar.  J Cell Physiol 1987, 133(3):491-498.
12. Iwamoto M, Sato K, Nakashima K, Fuchihata H, Suzuki F, Kato Y:
Regulation of colony formation of differentiated chondro-
cytes in soft agar by transforming growth factor-beta.  Bio-
chem Biophys Res Commun 1989, 159(3):1006-1011.
13. Aydelotte MB, Thonar EJ, Mollenhauer J, Flechtenmacher J: Culture
of chondrocytes in alginate gel: variations in conditions of
gelation influence the structure of the alginate gel, and the
arrangement and morphology of proliferating chondrocytes.
In Vitro Cell Dev Biol Anim 1998, 34(2):123-130.
14. Seyedin SM, Thompson AY, Bentz H, Rosen DM, McPherson JM,
Conti A, Siegel NR, Galluppi GR, Piez KA: Cartilage-inducing fac-
tor-A. Apparent identity to transforming growth factor-
beta.  J Biol Chem 1986, 261(13):5693-5695.
15. Urashima M, Hoshi Y, Shishikura A, Kamijo M, Kato Y, Akatsuka J,
Maekawa K: Umbilical cord blood as a rich source of imma-
ture hematopoietic stem cells.  Acta Paediatr Jpn 1994,
36(6):649-655.
16. Avraham S, Avraham H: Characterization of the novel focal
adhesion kinase RAFTK in hematopoietic cells.  Leuk Lym-
phoma 1997, 27(3–4):247-256.
17. Kleeff J, Maruyama H, Friess H, Buchler MW, Falb D, Korc M: Smad6
suppresses TGF-beta-induced growth inhibition in COLO-
357 pancreatic cancer cells and is overexpressed in pancre-
atic cancer.  Biochem Biophys Res Commun 1999, 255(2):268-273.
18. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW,
Falb D, Korc M: The TGF-beta signaling inhibitor Smad7
enhances tumorigenicity in pancreatic cancer.  Oncogene 1999,
18(39):5363-5372.
19. Peng B, Fleming JB, Breslin T, Grau AM, Fojioka S, Abbruzzese JL,
Evans DB, Ayers D, Wathen K, Wu T, et al.: Suppression of tum-
origenesis and induction of p15(ink4b) by Smad4/DPC4 in
human pancreatic cancer cells.  Clin Cancer Res 2002,
8(11):3628-3638.
20. Schwartz MA, Assoian RK: Integrins and cell proliferation: reg-
ulation of cyclin-dependent kinases via cytoplasmic signaling
pathways.  J Cell Sci 2001, 114(Pt 14):2553-2560.
21. Schwartz MA, Ginsberg MH: Networks and crosstalk: integrin
signalling spreads.  Nat Cell Biol 2002, 4(4):E65-68.
22. Walker JL, Assoian RK: Integrin-dependent signal transduction
regulating cyclin D1 expression and G1 phase cell cycle pro-
gression.  Cancer Metastasis Rev 2005, 24(3):383-393.
23. Besser D, Bromberg JF, Darnell JE Jr, Hanafusa H: A single amino
acid substitution in the v-Eyk intracellular domain results in
activation of Stat3 and enhances cellular transformation.
Mol Cell Biol 1999, 19(2):1401-1409.
24. Bromberg JF: Activation of STAT proteins and growth control.
Bioessays 2001, 23(2):161-169.
25. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S,
Wang T, Sinibaldi D, Coppola D, et al.: Constitutive Stat3 activity
up-regulates VEGF expression and tumor angiogenesis.
Oncogene 2002, 21(13):2000-2008.
26. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE,
McCubrey JA: JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-
ABL in cell cycle progression and leukemogenesis.  Leukemia
2004, 18(2):189-218.
27. Klampfer L: Signal transducers and activators of transcription
(STATs): Novel targets of chemopreventive and chemother-
apeutic drugs.  Curr Cancer Drug Targets 2006, 6(2):107-121.
28. Hiraki Y, Mitsui K, Endo N, Takahashi K, Hayami T, Inoue H, Shuku-
nami C, Tokunaga K, Kono T, Yamada M, et al.: Molecular cloning
of human chondromodulin-I, a cartilage-derived growth
modulating factor, and its expression in Chinese hamster
ovary cells.  Eur J Biochem 1999, 260(3):869-878.
29. Hotta T, Motoyama T, Watanabe H: Three human osteosarcoma
cell lines exhibiting different phenotypic expressions.  Acta
Pathol Jpn 1992, 42(8):595-603.
30. Motoyama T, Hotta T, Watanabe H, Kumanishi T, Ichikawa T,
Sekiguchi M: Differential production of interleukin 6 in human
osteosarcoma cells and the possible effects on neoplastic
bone metabolism.  Virchows Arch B Cell Pathol Incl Mol Pathol 1993,
63(5):277-281.
31. Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K,
Tokuda C, Saito I: Efficient generation of recombinant adeno-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2009, 9:166 http://www.biomedcentral.com/1471-2407/9/166
Page 12 of 12
(page number not for citation purposes)
viruses using adenovirus DNA-terminal protein complex and
a cosmid bearing the full-length virus genome.  Proc Natl Acad
Sci USA 1996, 93(3):1320-1324.
32. Hiraki Y, Shukunami C: Angiogenesis inhibitors localized in
hypovascular mesenchymal tissues: chondromodulin-I and
tenomodulin.  Connect Tissue Res 2005, 46(1):3-11.
33. Azizan A, Gaw JU, Govindraj P, Tapp H, Neame PJ: Chondromod-
ulin I and pleiotrophin gene expression in bovine cartilage
and epiphysis.  Matrix Biol 2000, 19(6):521-531.
34. Nakamichi Y, Shukunami C, Yamada T, Aihara K, Kawano H, Sato T,
Nishizaki Y, Yamamoto Y, Shindo M, Yoshimura K, et al.: Chondro-
modulin I is a bone remodeling factor.  Mol Cell Biol 2003,
23(2):636-644.
35. Starr R, Hilton DJ: Negative regulation of the JAK/STAT path-
way.  Bioessays 1999, 21(1):47-52.
36. Yoshioka M, Yuasa S, Matsumura K, Kimura K, Shiomi T, Kimura N,
Shukunami C, Okada Y, Mukai M, Shin H, et al.: Chondromodulin-I
maintains cardiac valvular function by preventing angiogen-
esis.  Nat Med 2006, 12(10):1151-1159.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/166/pre
pub